Bolt Biotherapeutics

BOLTNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$6.916 M

$3.59 +0.84%

Close of 21 Sept 2026

Revenue

$7.70M

#3205 by revenue

Earnings

-$33.4M

Loss-making

Shares outstanding

1,926,345

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#451Xenetic BiosciencesXBIO$7.01M
#452Enveric BiosciencesENVB$6.98M
#453Bolt BiotherapeuticsBOLT$6.92M
#454Curanex PharmaceuticalsCURX$6.85M
#455Ernexa TherapeuticsERNA$6.46M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of Bolt Biotherapeutics, worth $4.44K. Grants and option exercises are excluded.

William P. QuinnPresident, CEO and CFO$2.47K
637 shares at $3.88 on 5 Jun 2026 · filed 21 Sept 2026
Sarah NemecSenior VP, Finance and PAO$1.97K
509 shares at $3.88 on 5 Jun 2026 · filed 21 Sept 2026

What if Bolt Biotherapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$15,715,800

Per share 4,377,660× higher

Bitcoin $1.72T

$892,780.68

Per share 248,685× higher

Nvidia $5.48T

$2,844,692

Per share 792,393× higher

Or at a round number

$10.0M $20.0M $50.0M $100.0M

Where these numbers come from

Share counts and financials for Bolt Biotherapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.